Evidence map›Paper›PMID 37230953›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023

Associations with age and glomerular filtration rate in a referred population with chronic kidney disease: methods and baseline data from a UK multicentre cohort study (NURTuRE-CKD).

Maarten W Taal, Bethany Lucas, Paul Roderick, Paul Cockwell, David C Wheeler, Moin A Saleem, Simon D S Fraser, Rosamonde E Banks, Tim Johnson, Lorna J Hale and 14 more

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04084145 (National Unified Renal Translation Research Enterprise - Chronic Kidney Disease), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04084145 active not recruitingnot on this map

National Unified Renal Translation Research Enterprise - Chronic Kidney Disease

TypeobservationalSponsorUniversity of NottinghamRan2016 to 2032Enrolled3,004ConditionsChronic Kidney Diseases
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Sex-Associated Biomarker Differences in CKD Progression and Mortality.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  8. Article
  9. Article
  10. Biomarkers of Kidney Failure and All-Cause Mortality in CKD.Journal of the American Society of Nephrology : JASN · 2025
    Article
  11. Article
  12. Article
  13. Enhancing collaboration between academia and industry in kidney disease research.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  14. Toward Noninvasive Biomarkers of Renal Senescence.Journal of the American Society of Nephrology : JASN · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 14 institutions in 3 countries.

Maarten W TaalCentre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0002-9065-212X
Bethany LucasCentre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
Paul RoderickSchool of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.
Paul CockwellDepartment of Renal Medicine, Queen Elizabeth Hospital, University Hospitals of Birmingham, Birmingham, UK.
David C WheelerUniversity College London, London, UK.
Moin A SaleemBristol Renal and Children's Renal Unit, Bristol Medical School, University of Bristol, Bristol, UK.
Simon D S FraserSchool of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID 0000-0002-4172-4406
Rosamonde E BanksLeeds Institute of Medical Research at St James's, School of Medicine, University of Leeds, Leeds, UK.
Tim JohnsonExperimental Renal Medicine, Human Metabolism and Oncology, The Medical School, University of Sheffield, Sheffield, UK.
Lorna J HaleUCB Pharma, Slough, UK.
Uwe AndagEvotec International GmbH, Göttingen, Germany.
Philipp SkroblinEvotec International GmbH, Göttingen, Germany.
Michaela BayerlovaEvotec International GmbH, Göttingen, Germany.
Robert UnwinAstraZeneca BioPharmaceuticals, Cambridge Biomedical Campus, Cambridge, UK.
Nicolas VuilleumierDiagnostics Department, Laboratory Medicine Division, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Rodolphe DusaulcyDiagnostics Department, Laboratory Medicine Division, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Fiona RobertsonCentre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
Elizabeth ColbyBristol Renal and Children's Renal Unit, Bristol Medical School, University of Bristol, Bristol, UK.
David PitcherUnited Kingdom Renal Registry, Bristol, UK.
Fiona BraddonUnited Kingdom Renal Registry, Bristol, UK.
Melissa BenaventeCentre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
Elaine DaviesKidney Research UK, Peterborough, UK.
Michael NationKidney Research UK, Peterborough, UK.
Philip A KalraRenal Services, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
University of Nottingham · GBEvotec (Germany) · DEKidney Research UK · GBRenal Association · GBUniversity Hospital of Geneva · CHUniversity of Bristol · GBUniversity of Southampton · GBAstraZeneca (United Kingdom) · GBQueen Elizabeth Hospital Birmingham · GBSalford Royal Hospital · GBUCB Pharma (United Kingdom) · GBUniversity College London · GBUniversity of Leeds · GBUniversity of Sheffield · GB

Funding

Medical Research Council MR/R013942/1
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is common but heterogenous and is associated with multiple adverse outcomes. The National Unified Renal Translational Research Enterprise (NURTuRE)-CKD cohort was established to investigate risk factors for clinically important outcomes in persons with CKD referred to secondary care.

methodsEligible participants with CKD stages G3-4 or stages G1-2 plus albuminuria >30 mg/mmol were enrolled from 16 nephrology centres in England, Scotland and Wales from 2017 to 2019. Baseline assessment included demographic data, routine laboratory data and research samples. Clinical outcomes are being collected over 15 years by the UK Renal Registry using established data linkage. Baseline data are presented with subgroup analysis by age, sex and estimated glomerular filtration rate (eGFR).

resultsA total of 2996 participants was enrolled. Median (interquartile range) age was 66 (54-74) years, eGFR 33.8 (24.0-46.6) mL/min/1.73 m2 and urine albumin to creatinine ratio 209 (33-926) mg/g; 58.5% were male. Of these participants, 1883 (69.1%) were in high-risk CKD categories. Primary renal diagnosis was CKD of unknown cause in 32.3%, glomerular disease in 23.4% and diabetic kidney disease in 11.5%. Older participants and those with lower eGFR had higher systolic blood pressure and were less likely to be treated with renin-angiotensin system inhibitors (RASi) but were more likely to receive a statin. Female participants were less likely to receive a RASi or statin.

conclusionsNURTuRE-CKD is a prospective cohort of persons who are at relatively high risk of adverse outcomes. Long-term follow-up and a large biorepository create opportunities for research to improve risk prediction and to investigate underlying mechanisms to inform new treatment development.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsRenal Insufficiency, ChronicAgedAlbuminuriaEnglandFemaleGlomerular Filtration RateHumansMaleProspective StudiesRisk FactorsHydroxymethylglutaryl-CoA Reductase Inhibitorsalbuminuriachronic kidney diseasecohort studyrisk profilesex

Identifiers

PMID37230953
PMCPMC10615633
OpenAlexW4378347867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.